Login| Sign Up| Help| Contact|

Patent Searching and Data


Title:
NOVEL APPLICATION OF GZD824 AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF IN TREATING DISEASES
Document Type and Number:
WIPO Patent Application WO/2018/018950
Kind Code:
A1
Abstract:
Disclosed is an application of (3-((1H-pyrazol[3,4-b]pyridine-5-substituted)ethinyl)-4-methyl-N-(4-((4-methylpiperazine-1-substituted)methyl)-3-(trifluoromethyl)phenyl)benzamide) and pharmaceutically acceptable salts thereof in preparing drugs for treating acute lymphoblastic leukemia, and in particular, precursor B-cell lymphoblastic leukemia.

More Like This:
JP5215666BAY43-9006 Thermodynamically stable form of tosylate
JP2002529429INDUSTRIAL APPLICABILITY Treatment of a patient undergoing BMT or PBSC transplantation with a chimeric anti-CD20 antibody.
JP2023522691Inhibitor of human epididymal protein 4
Inventors:
LI PENG (CN)
YE WEI (CN)
DING KE (CN)
LU XIAOYUN (CN)
Application Number:
PCT/CN2017/081173
Publication Date:
February 01, 2018
Filing Date:
April 20, 2017
Export Citation:
Click for automatic bibliography generation   Help
Assignee:
GUANGZHOU SHUNJIAN PHARMACEUTICALS CO LTD (CN)
International Classes:
A61P35/02; A61K31/496
Foreign References:
CN101885722A2010-11-17
CN103539784A2014-01-29
Other References:
See also references of EP 3488850A4
Attorney, Agent or Firm:
ADVANCE CHINA IP LAW OFFICE (CN)
Download PDF:
View/Download PDF      PDF Help



 
Previous Patent: POWER INTERFACE, MOBILE TERMINAL, AND POWER ADAPTER

Next Patent: NOVEL FOLDABLE BOX AND DISMOUNTING METHOD THEREOF